Baseline visceral fat area and early visceral fat loss predict survival in HER2-negative advanced gastroesophageal adenocarcinoma treated with immunochemotherapy
{{output}}
Immune checkpoint inhibitor (ICI)-based chemotherapy has improved outcomes in human epidermal growth factor receptor 2 (HER2)-negative advanced gastroesophageal adenocarcinoma (GEA), but clinically accessible prognostic biomarkers remain limited. This study ev... ...
